To see the other types of publications on this topic, follow the link: P-PBPK model.

Journal articles on the topic 'P-PBPK model'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'P-PBPK model.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mi, Kun, Shanju Pu, Yixuan Hou, et al. "Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic–Pharmacodynamic Model." International Journal of Molecular Sciences 23, no. 7 (2022): 3722. http://dx.doi.org/10.3390/ijms23073722.

Full text
Abstract:
Model informed drug development is a valuable tool for drug development and clinical application due to its ability to integrate variability and uncertainty of data. This study aimed to determine an optimal dosage of ceftiofur against P. multocida by ex vivo pharmacokinetic/pharmacodynamic (PK/PD) model and validate the dosage regimens by Physiological based Pharmacokinetic-Pharmacodynamic (PBPK/PD) model. The pharmacokinetic profiles of ceftiofur both in plasma and bronchoalveolar lavage fluid (BALF) are determined. PD performance of ceftiofur against P. multocida was investigated. By establi
APA, Harvard, Vancouver, ISO, and other styles
2

Jeong, Yoo-Seong, Min-Soo Kim, Nora Lee, et al. "Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans." Pharmaceutics 13, no. 6 (2021): 813. http://dx.doi.org/10.3390/pharmaceutics13060813.

Full text
Abstract:
Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB) family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD). Physiologically based pharmacokinetic (PBPK) models predict drug interactions as pharmacokinetic profiles in biological matrices can be mechanistically simulated. Here, we propose an optimized and validated PBPK model for fexuprazan by integrating in vitro, in vivo, and in silico data. The extent of fexuprazan tissue distribution
APA, Harvard, Vancouver, ISO, and other styles
3

Dallmann, A., P. Mian, P. Annaert, M. Pfister, K. Allegaert, and J. van den Anker. "P21 PBPK modeling in pregnancy: achievements, shortcomings and future perspectives." Archives of Disease in Childhood 104, no. 6 (2019): e25.2-e25. http://dx.doi.org/10.1136/archdischild-2019-esdppp.59.

Full text
Abstract:
BackgroundPhysiologically-based pharmacokinetic (PBPK) models are considered a promising approach to better characterize and anticipate the effect of physiological changes on pharmacokinetics in pregnant women. Consequently, multiple pregnancy PBPK models have been developed and verified over the past years. Using acetaminophen (paracetamol) as example, PBPK modeling can provide specific insights into the expected pharmacokinetic changes throughout pregnancy.MethodsTo obtain an overview of pregnancy PBPK models, the scientific literature was systematically screened for publications with a focu
APA, Harvard, Vancouver, ISO, and other styles
4

Nauwelaerts, Nina, Julia Macente, Neel Deferm, et al. "Generic Workflow to Predict Medicine Concentrations in Human Milk Using Physiologically-Based Pharmacokinetic (PBPK) Modelling—A Contribution from the ConcePTION Project." Pharmaceutics 15, no. 5 (2023): 1469. http://dx.doi.org/10.3390/pharmaceutics15051469.

Full text
Abstract:
Women commonly take medication during lactation. Currently, there is little information about the exposure-related safety of maternal medicines for breastfed infants. The aim was to explore the performance of a generic physiologically-based pharmacokinetic (PBPK) model to predict concentrations in human milk for ten physiochemically diverse medicines. First, PBPK models were developed for “non-lactating” adult individuals in PK-Sim/MoBi v9.1 (Open Systems Pharmacology). The PBPK models predicted the area-under-the-curve (AUC) and maximum concentrations (Cmax) in plasma within a two-fold error.
APA, Harvard, Vancouver, ISO, and other styles
5

R.P., Sharma, Schuhmacher M., and Kumar V. "The development of a pregnancy PBPK Model for Bisphenol A and its evaluation with the available biomonitoring data." Science of the Total Environment 624 (May 15, 2018): 55–68. https://doi.org/10.1016/j.scitotenv.2017.12.023.

Full text
Abstract:
Recent studies suggest universal fetal exposure to Bisphenol A (BPA) and its association with the adverse birth outcomes. Estimation of the fetal plasma BPA concentration from the maternal plasma BPA would be highly useful to predict its associated risk to this specific population. The objective of current work is to develop a pregnancy-physiologically based pharmacokinetic (P-PBPK) model to predict the toxicokinetic profile of BPA in the fetus during gestational growth, and to evaluate the developed model using biomonitoring data obtained from different pregnancy cohort studies. To achieve th
APA, Harvard, Vancouver, ISO, and other styles
6

Yang, Zhuan, Yuchen Qu, Yewen Sun, Jie Pan, Tong Zhou, and Yunli Yu. "Evaluation of Drug–Drug Interactions Between Clarithromycin and Direct Oral Anticoagulants Using Physiologically Based Pharmacokinetic Models." Pharmaceutics 16, no. 11 (2024): 1449. http://dx.doi.org/10.3390/pharmaceutics16111449.

Full text
Abstract:
Objective: This study assessed the pharmacokinetic (PK) interactions between clarithromycin (a P-glycoprotein [P-gp] inhibitor) and four direct oral anticoagulants (DOACs) (P-gp substrates) using physiologically based PK (PBPK) models to elucidate the influence of P-gp in the interaction between them. Methods: PBPK models for clarithromycin, DABE–dabigatran (DAB), rivaroxaban, apixaban, and edoxaban were constructed using GastroPlus™ (version 9.9), based on physicochemical data and PK parameters from the literature. The models were optimized and validated in healthy subjects. We evaluated the
APA, Harvard, Vancouver, ISO, and other styles
7

Costa, Bárbara, Maria João Gouveia, and Nuno Vale. "PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management." Pharmaceutics 16, no. 9 (2024): 1163. http://dx.doi.org/10.3390/pharmaceutics16091163.

Full text
Abstract:
This study aimed to model the pharmacokinetics of lamotrigine (LTG) and efavirenz (EFV) in pregnant women using physiologically based pharmacokinetic (PBPK) and pregnancy-specific PBPK (p-PBPK) models. For lamotrigine, the adult PBPK model demonstrated accurate predictions for pharmacokinetic parameters. Predictions for the area under the curve (AUC) and peak plasma concentration (Cmax) generally agreed well with observed values. During pregnancy, the PBPK model accurately predicted AUC and Cmax with a prediction error (%PE) of less than 25%. The evaluation of the EFV PBPK model revealed mixed
APA, Harvard, Vancouver, ISO, and other styles
8

Ali-Daoud, Yourdasmine, Cleo Tebby, Rémy Beaudouin, and Céline Brochot. "Development of a physiologically based toxicokinetic model for lead in pregnant women: the role of bone tissue in the maternal and fetal internal exposure." Toxicology and Applied Pharmacology 476 (August 29, 2023): 116651. https://doi.org/10.5281/zenodo.8297909.

Full text
Abstract:
Epidemiological studies have shown associations between prenatal exposure to lead (Pb) and neurodevelopmental effects in young children. Prenatal exposure is generally characterized by measuring the concentration in the umbilical cord at delivery or in the maternal blood during pregnancy. To assess internal Pb exposure during prenatal life, we developed a pregnancy physiologically based pharmacokinetic (p-PBPK) model that to simulates Pb levels in blood and target tissues in the fetus, especially during critical periods for brain development. An existing Pb PBPK model was adapted to pregnant w
APA, Harvard, Vancouver, ISO, and other styles
9

Kovar, Lukas, Christina Schräpel, Dominik Selzer, et al. "Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates." Pharmaceutics 12, no. 6 (2020): 578. http://dx.doi.org/10.3390/pharmaceutics12060578.

Full text
Abstract:
Buprenorphine plays a crucial role in the therapeutic management of pain in adults, adolescents and pediatric subpopulations. However, only few pharmacokinetic studies of buprenorphine in children, particularly neonates, are available as conducting clinical trials in this population is especially challenging. Physiologically-based pharmacokinetic (PBPK) modeling allows the prediction of drug exposure in pediatrics based on age-related physiological differences. The aim of this study was to predict the pharmacokinetics of buprenorphine in pediatrics with PBPK modeling. Moreover, the drug-drug i
APA, Harvard, Vancouver, ISO, and other styles
10

Pilla Reddy, Venkatesh, Adrian J. Fretland, Diansong Zhou, et al. "Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors." Cancer Chemotherapy and Pharmacology 88, no. 3 (2021): 451–64. http://dx.doi.org/10.1007/s00280-021-04302-5.

Full text
Abstract:
Abstract Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone (R-CHOP) therapy. The addition of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib to R-CHOP therapy results in increased toxicity versus R-CHOP alone, including higher incidence of peripheral neuropathy. Vincristine is a substrate of P-glycoprotein (P-gp, ABCB1); drugs that inhibit P-gp could potentially cause increased toxicity when co-administered wi
APA, Harvard, Vancouver, ISO, and other styles
11

Yang, Yiting, Ping Li, Zexin Zhang, Zhongjian Wang, Li Liu, and Xiaodong Liu. "Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes." International Journal of Molecular Sciences 21, no. 19 (2020): 7023. http://dx.doi.org/10.3390/ijms21197023.

Full text
Abstract:
Uptake transporter organic anion transporting polypeptides (OATPs), efflux transporters (P-gp, BCRP and MRP2) and cytochrome P450 enzymes (CYP450s) are widely expressed in the liver, intestine or kidney. They coordinately work to control drug disposition, termed as “interplay of transporters and enzymes”. Cyclosporine A (CsA) is an inhibitor of OATPs, P-gp, MRP2, BCRP and CYP3As. Drug–drug interaction (DDI) of CsA with victim drugs occurs via disordering interplay of transporters and enzymes. We aimed to establish a whole-body physiologically-based pharmacokinetic (PBPK) model which predicts d
APA, Harvard, Vancouver, ISO, and other styles
12

Wills, Kenneth H., Stephen J. Behan, Michael J. Nance, et al. "Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure." Pharmaceutics 14, no. 1 (2021): 47. http://dx.doi.org/10.3390/pharmaceutics14010047.

Full text
Abstract:
Background: Clozapine is a key antipsychotic drug for treatment-resistant schizophrenia but exhibits highly variable pharmacokinetics and a propensity for serious adverse effects. Currently, these challenges are addressed using therapeutic drug monitoring (TDM). This study primarily sought to (i) verify the importance of covariates identified in a prior clozapine population pharmacokinetic (popPK) model in the absence of environmental covariates using physiologically based pharmacokinetic (PBPK) modelling, and then to (ii) evaluate the performance of the popPK model as an adjunct or alternativ
APA, Harvard, Vancouver, ISO, and other styles
13

Kim, Min-Soo, Nora Lee, Areum Lee, Yoon-Jee Chae, Suk-Jae Chung, and Kyeong-Ryoon Lee. "Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans." Pharmaceuticals 15, no. 6 (2022): 709. http://dx.doi.org/10.3390/ph15060709.

Full text
Abstract:
Fexuprazan is a potassium-competitive acid blocker (P-CAB). The compounds in this newly developed drug family suppress intragastric acidity. As there are already other acid-suppressing drugs on the market, such as H2 antagonists and proton pump inhibitors (PPIs), it would be informative to compare the biological effects of fexuprazan against another approved drug with the same indication. The drug concentration predicted by the pharmacokinetic (PK) model could serve as an input function for a pharmacodynamic (PD) model. The apparent pharmacokinetics of fexuprazan could be described by a simple
APA, Harvard, Vancouver, ISO, and other styles
14

Bachelet, Delphine, Marc-André Verner, Monica Neri, et al. "Breast Cancer and Exposure to Organochlorines in the CECILE Study: Associations with Plasma Levels Measured at the Time of Diagnosis and Estimated during Adolescence." International Journal of Environmental Research and Public Health 16, no. 2 (2019): 271. http://dx.doi.org/10.3390/ijerph16020271.

Full text
Abstract:
Exposure to environmental chemicals with hormonal effects, such as organochlorine compounds (OCs), during developmental periods of breast cells may have an impact on the incidence of breast cancer later in life. However, the assessment of exposure to these chemicals that occurred in early life at the time of breast cancer development in adult women is a difficult challenge in epidemiological studies. Plasma levels of the OCs p,p’-dichlorodiphenyl dichloroethene (DDE) and polychlorinated biphenyl congener 153 (PCB153) were measured in 695 cases and 1055 controls of a population-based case-contr
APA, Harvard, Vancouver, ISO, and other styles
15

Ruan, Hao, Xiaoting Geng, Zijing Situ, et al. "From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets." Pharmaceuticals 18, no. 4 (2025): 562. https://doi.org/10.3390/ph18040562.

Full text
Abstract:
Background: Candesartan cilexetil, a Biopharmaceutics Classification System (BCS) II prodrug, demonstrates compromised bioavailability attributable to its limited aqueous solubility coupled with P-glycoprotein (P-gp)-mediated efflux and hepatic first-pass metabolism, thereby introducing complexities in generic drug bioequivalence assessments. With the rapid advancement of computational technologies, the integration of biorelevant dissolution methodologies with physiologically based pharmacokinetic (PBPK) modeling is emerging as a transformative paradigm in advancing bioequivalence evaluation s
APA, Harvard, Vancouver, ISO, and other styles
16

Berghausen, Joerg, Frank Hans Seiler, Nathalie Gobeau, and Bernard Faller. "Simulated rat intestinal fluid improves oral exposure prediction for poorly soluble compounds over a wide dose range." ADMET & DMPK 4, no. 1 (2016): 35. http://dx.doi.org/10.5599/admet.4.1.258.

Full text
Abstract:
<p class="ADMETabstracttext">Solubility can be the absorption limiting factor for drug candidates and is therefore a very important input parameter for oral exposure prediction of compounds with limited solubility. Biorelevant media of the fasted and fed state have been published for humans, as well as for dogs in the fasted state. In a drug discovery environment, rodents are the most common animal model to assess the oral exposure of drug candidates. In this study a rat simulated intestinal fluid (rSIF) is proposed as a more physiologically relevant media to describe drug solubility in
APA, Harvard, Vancouver, ISO, and other styles
17

Liu, Rongrui, Tim R. Zacharewski, Rory B. Conolly, and Qiang Zhang. "A Physiologically Based Pharmacokinetic (PBPK) Modeling Framework for Mixtures of Dioxin-like Compounds." Toxics 10, no. 11 (2022): 700. http://dx.doi.org/10.3390/toxics10110700.

Full text
Abstract:
Humans are exposed to persistent organic pollutants, such as dioxin-like compounds (DLCs), as mixtures. Understanding and predicting the toxicokinetics and thus internal burden of major constituents of a DLC mixture is important for assessing their contributions to health risks. PBPK models, including dioxin models, traditionally focus on one or a small number of compounds; developing new or extending existing models for mixtures often requires tedious, error-prone coding work. This lack of efficiency to scale up for multi-compound exposures is a major technical barrier toward large-scale mixt
APA, Harvard, Vancouver, ISO, and other styles
18

Jaisupa, *Nattapon, Michael Ashton, and Sofia Birgersson. "DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL TO PREDICT PLASMA AND BRAIN EXPOSURE FOLLOWING ADMINISTRATION OF VALPROIC ACID AND CLOBAZAM IN COMBINATION TREATMENT REGIMEN FOR DRAVET SYNDROME IN CHILDREN." International Journal of Neuropsychopharmacology 28, Supplement_1 (2025): i157—i158. https://doi.org/10.1093/ijnp/pyae059.272.

Full text
Abstract:
Abstract Background Combination of valproic acid and clobazam is considered as a first-line option for Dravet syndrome (Wirrell and Nabbout, 2019). Therapeutic trough plasma concentration of valproic acid has been reported in the literature to be 50-100 mg/mL (Damegunta, 2014), and for clobazam between 30-300 ng/mL (de Leon, Spina and Diaz, 2013). A PBPK model to predict concentration-time data of valproic acid and clobazam in combination has not been established yet. Having such a model could be clinically useful for predicting the exposures of these drugs and forecasting clinical outcome. Ai
APA, Harvard, Vancouver, ISO, and other styles
19

Ciffroy, Philippe, T. Tanaka, E. Johansson, and C. Brochot. "Linking fate model in freshwater and PBPK model to assess human internal dosimetry of B(a)P associated with drinking water." Environmental Geochemistry and Health 33, no. 4 (2011): 371–87. http://dx.doi.org/10.1007/s10653-011-9382-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Gaohua, Lu, Khaled Abduljalil, Masoud Jamei, Trevor N. Johnson, and Amin Rostami-Hodjegan. "A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4." British Journal of Clinical Pharmacology 74, no. 5 (2012): 873–85. http://dx.doi.org/10.1111/j.1365-2125.2012.04363.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Smith, Jordan N., Kari A. Gaither, and Paritosh Pande. "Competitive Metabolism of Polycyclic Aromatic Hydrocarbons (PAHs): An Assessment Using In Vitro Metabolism and Physiologically Based Pharmacokinetic (PBPK) Modeling." International Journal of Environmental Research and Public Health 19, no. 14 (2022): 8266. http://dx.doi.org/10.3390/ijerph19148266.

Full text
Abstract:
Humans are routinely exposed to complex mixtures such as polycyclic aromatic hydrocarbons (PAHs) rather than to single compounds, as are often assessed for hazards. Cytochrome P450 enzymes (CYPs) metabolize PAHs, and multiple PAHs found in mixtures can compete as substrates for individual CYPs (e.g., CYP1A1, CYP1B1, etc.). The objective of this study was to assess competitive inhibition of metabolism of PAH mixtures in humans and evaluate a key assumption of the Relative Potency Factor approach that common human exposures will not cause interactions among mixture components. To test this objec
APA, Harvard, Vancouver, ISO, and other styles
22

Russo, Francesca M., Felix De Bie, Ryan Hodges, Alan Flake, and Jan Deprest. "Sildenafil for Antenatal Treatment of Congenital Diaphragmatic Hernia: From Bench to Bedside." Current Pharmaceutical Design 25, no. 5 (2019): 601–8. http://dx.doi.org/10.2174/1381612825666190320151856.

Full text
Abstract:
Background: Persistent pulmonary hypertension (PPH) is one of the main causes of mortality and morbidity in infants affected by congenital diaphragmatic hernia (CDH). Since the structural changes that lead to PPH take place already in utero, a treatment starting in the prenatal phase may prevent the occurrence of this complication. Objective: To summarize the development process of antenatal sildenafil for CDH. Methods: The pharmacokinetics and efficacy of sildenafil have been assessed in the rat and the rabbit model. The transfer of the drug through the human placenta has been measured with t
APA, Harvard, Vancouver, ISO, and other styles
23

Templeton, Ian E., Terry Podoll, Cecile Marie Krejsa, and J. Greg Slatter. "A Mechanistic Physiologically Based Pharmacokinetic (PBPK) Drug Interaction Model for the Mouse Double Minute 2 (MDM2) Inhibitor KRT-232." Blood 136, Supplement 1 (2020): 9–10. http://dx.doi.org/10.1182/blood-2020-135987.

Full text
Abstract:
Background: KRT-232 is a potent, selective, orally available, targeted inhibitor of human MDM2 homolog interactions with tumor suppressor protein 53 (p53). KRT-232 is under development for treatment of myeloproliferative neoplasms, acute myeloid leukemia and Merkel cell carcinoma. KRT-232 is a highly permeable 568.6 g/mol, monoprotic carboxylic acid (pKa 4.35); elimination involves primarily biliary-fecal excretion of an acyl glucuronide metabolite (M1) and enteric glucuronide hydrolysis with enterohepatic recirculation of parent drug. M1 is a 744.7 g/mol monoprotic acid with pKa 3.32 and 1/5t
APA, Harvard, Vancouver, ISO, and other styles
24

Verscheijden, Laurens F. M., Jan B. Koenderink, Saskia N. de Wildt, and Frans G. M. Russel. "Differences in P-glycoprotein activity in human and rodent blood–brain barrier assessed by mechanistic modelling." Archives of Toxicology 95, no. 9 (2021): 3015–29. http://dx.doi.org/10.1007/s00204-021-03115-y.

Full text
Abstract:
AbstractVariation in the efficacy and safety of central nervous system drugs between humans and rodents can be explained by physiological differences between species. An important factor could be P-glycoprotein (Pgp) activity in the blood–brain barrier (BBB), as BBB expression of this drug efflux transporter is reportedly lower in humans compared to mouse and rat and subject to an age-dependent increase. This might complicate animal to human extrapolation of brain drug disposition and toxicity, especially in children. In this study, the potential species-specific effect of BBB Pgp activity on
APA, Harvard, Vancouver, ISO, and other styles
25

Nguyen, Dung N., Xiusheng Miao, Mindy Magee, Guoying Tai, Peter D. Gorycki, and Katy P. Moore. "1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models." Open Forum Infectious Diseases 7, Supplement_1 (2020): S669. http://dx.doi.org/10.1093/ofid/ofaa439.1497.

Full text
Abstract:
Abstract Background Fostemsavir (FTR) is an oral prodrug of the first-in-class attachment inhibitor temsavir (TMR) which is being evaluated in patients with multidrug resistant HIV-1 infection. In vitro studies indicated that TMR and its 2 major metabolites are inhibitors of organic cation transporters (OCT)1, OCT2, and multidrug and toxin extrusion transporters (MATEs). To assess the clinical relevance, of OCT and MATE inhibition, mechanistic static DDI prediction with calculated Imax,u/IC50 ratios was below the cut-off limits for a DDI flag based on FDA guidelines and above the cut-off limit
APA, Harvard, Vancouver, ISO, and other styles
26

Kato, Takafumi, Tsuyoshi Mikkaichi, Yasushi Yoshigae, et al. "Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model." International Journal of Pharmaceutics 597 (March 2021): 120349. http://dx.doi.org/10.1016/j.ijpharm.2021.120349.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Liu, Jian, Swan Lin, Anthony Huynh, and Weiwei Tan. "Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib." Pharmaceutics 16, no. 1 (2024): 118. http://dx.doi.org/10.3390/pharmaceutics16010118.

Full text
Abstract:
Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibitors decreased dacomitinib exposure. This analysis summarizes the effect of Histamine-2 receptor antagonists (H2RAs) on dacomitinib exposure. A within-patient comparison of the steady-state trough concentrations (Ctrough,ss) of dacomitinib and its active metabolite and active moiety with and without concomitant use of H2RAs was conducted using a linear mixed effe
APA, Harvard, Vancouver, ISO, and other styles
28

Desai, Amit, Laura Kovanda, Christopher Lademacher, et al. "1396. Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 Months: <18 Years by Physiologically Based Pharmacokinetic Modeling." Open Forum Infectious Diseases 5, suppl_1 (2018): S429—S430. http://dx.doi.org/10.1093/ofid/ofy210.1227.

Full text
Abstract:
Abstract Background Best practice to establish dosage regimens for “first-in-pediatric” clinical trials requires knowledge of efficacious and safe exposures in adults. Methods Pediatric equivalent doses were predicted for patients aged 6 months and &amp;lt;18 years using physiologically based pharmacokinetic (PBPK) modeling, and compared with predictions by allometric scaling. All simulations were completed using PK-Sim®, which implements a whole-body PBPK model with 15 organs and appropriate maturation of anatomical and physiological parameters for children. The adult PBPK model was built usi
APA, Harvard, Vancouver, ISO, and other styles
29

Zhou, Kaixiang, Meixia Huo, Wenjin Ma, et al. "Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion." Pharmaceutics 13, no. 5 (2021): 602. http://dx.doi.org/10.3390/pharmaceutics13050602.

Full text
Abstract:
Zoonotic intestinal pathogens threaten human health and cause huge economic losses in farming. Enrofloxacin (ENR) shows high antibacterial activity against common intestinal bacteria. However, its poor palatability and low aqueous solubility limit the clinical application of ENR. To obtain an ENR oral preparation with good palatability and high solubility, a granule containing an amorphous ENR solid dispersion (ENR-SD) was prepared. Meanwhile, a PBPK model of ENR in pigs was built based on the physiological parameters of pigs and the chemical-specific parameters of ENR to simulate the pharmaco
APA, Harvard, Vancouver, ISO, and other styles
30

Mian, P., K. Allegaert, S. Conings, et al. "P66 Characterization of the pharmacokinetics of acetaminophen and its metabolites in the fetus through integration of placental transfer in a physiologically based pharmacokinetic model." Archives of Disease in Childhood 104, no. 6 (2019): e44.2-e45. http://dx.doi.org/10.1136/archdischild-2019-esdppp.104.

Full text
Abstract:
BackgroundLittle is known about fetal acetaminophen (paracetamol) pharmacokinetics and its potential for toxicity, despite the frequent use of acetaminophen during pregnancy. The aim of this study was to develop a feto-maternal physiologically based pharmacokinetic model (f-m PBPK) to predict placental transfer and PK of acetaminophen and its metabolites in fetus at term pregnancy.MethodsPreviously, a pregnancy PBPK model was developed for prediction of maternal PK of acetaminophen and its metabolites. This model was structurally extended with the fetal liver, and quantitative information on t
APA, Harvard, Vancouver, ISO, and other styles
31

Li, Yuezhe, A. Katharina Wilkins, Tim Knab, and Joseph P. Boni. "Abstract 875: Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL." Cancer Research 84, no. 6_Supplement (2024): 875. http://dx.doi.org/10.1158/1538-7445.am2024-875.

Full text
Abstract:
Abstract Introduction: CD19 and CD20, B-lymphocyte surface antigens, are clinically validated therapeutic targets for the treatment of B-cell malignancies. Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is an antibody-drug conjugate comprising an anti-CD19 antibody conjugated to a pyrrolobenzodiazepine dimer cytotoxin. Mosunetuzumab (Mosun) and glofitamab (Glofit) are CD20 × CD3 T-cell-engaging bispecific antibodies (bsAbs) that redirect T cells to eliminate malignant B cells. These agents target a different B-cell surface antigen than Lonca; hence, combining Lonca with either on
APA, Harvard, Vancouver, ISO, and other styles
32

Türk, Denise, Nina Hanke, and Thorsten Lehr. "A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions." Pharmaceutics 12, no. 11 (2020): 1074. http://dx.doi.org/10.3390/pharmaceutics12111074.

Full text
Abstract:
Trimethoprim is a frequently-prescribed antibiotic and therefore likely to be co-administered with other medications, but it is also a potent inhibitor of multidrug and toxin extrusion protein (MATE) and a weak inhibitor of cytochrome P450 (CYP) 2C8. The aim of this work was to develop a physiologically-based pharmacokinetic (PBPK) model of trimethoprim to investigate and predict its drug–drug interactions (DDIs). The model was developed in PK-Sim®, using a large number of clinical studies (66 plasma concentration–time profiles with 36 corresponding fractions excreted in urine) to describe the
APA, Harvard, Vancouver, ISO, and other styles
33

Marok, Fatima Zahra, Jan-Georg Wojtyniak, Laura Maria Fuhr, et al. "A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators." Pharmaceutics 15, no. 2 (2023): 679. http://dx.doi.org/10.3390/pharmaceutics15020679.

Full text
Abstract:
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its metabolites that predominantly accumulate in the liver. This work aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model of ketoconazole and its metabolites for fasted and fed states and to investigate the impact of ketoconazole’s metabolites on its DDI potential. The parent–
APA, Harvard, Vancouver, ISO, and other styles
34

Pepin, Xavier J. H., Natalie J. Sanderson, Alexander Blanazs, Shveta Grover, Timothy G. Ingallinera, and James C. Mann. "Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input." European Journal of Pharmaceutics and Biopharmaceutics 142 (September 2019): 421–34. http://dx.doi.org/10.1016/j.ejpb.2019.07.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

M., Schuhmacher, Fàbrega F., Kumar V., García F., Nadal M., and L. Domingo J. "A PBPK model to estimate PCDD/F levels in adipose tissue: comparison with experimental values of residents near a hazardous waste incinerator." Environment International 73 (August 10, 2014): 150–57. https://doi.org/10.1016/j.envint.2014.07.020.

Full text
Abstract:
This study was aimed at determining the concentrations of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans (PCDD/Fs) in 15 samples of adipose tissue from subjects who had been living in the vicinity of a hazardous waste incinerator (HWI). The results were compared with levels obtained in previous surveys carried out in 1998 (baseline study), 2002 and 2007. The current (2013) concentrations of PCDD/Fs in adipose tissue ranged from 2.8 to 46.3 pg WHO-TEQ/g fat (mean and median concentrations: 11.5 and 7.4 pg WHO-TEQ/g fat, respectively), being significantly lower (64%) than th
APA, Harvard, Vancouver, ISO, and other styles
36

Xie, Yuewu, Huixiang Liu, Xiaoyue Chen, and Jie Xing. "The Effect of Gastric pH on the Pharmacokinetics-pharmacodynamics of Naphthoquine in Rodents, as well as in Human Predicted Using a PBPK Model." Current Drug Metabolism 22, no. 5 (2021): 363–71. http://dx.doi.org/10.2174/1389200222666210129102411.

Full text
Abstract:
Background: Fixed-dose combination of artemisinin and naphthoquine (NQ) is a new artemisinin- based combination therapy for the treatment of uncomplicated Plasmodium falciparum. NQ absorption has been reported to be affected by food in humans. Objectives: The effect of gastric pH on NQ pharmacokinetics and antiplasmodial activity was investigated. Methods: The pharmacokinetic profiles of NQ were studied in healthy rodents after an oral dose of NQ with or without gastric pH modulators, i.e., pentagastrin (stimulator) and famotidine (suppressant). The effect of gastric pH on NQ exposures in huma
APA, Harvard, Vancouver, ISO, and other styles
37

Fenneteau, F., J. Li, L. Couture, J. Turgeon, and F. Nekka. "Prediction of the disposition of a P-gp substrate in wild-type and knockout mice tissues: Development of a physiologically based pharmacokinetic (PBPK) model and its global sensitivity analysis." PAMM 7, no. 1 (2007): 1121905–6. http://dx.doi.org/10.1002/pamm.200700608.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

del Río, A., C. García-de-la-Mària, J. M. Entenza та ін. "Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus". Antimicrobial Agents and Chemotherapy 60, № 1 (2015): 478–86. http://dx.doi.org/10.1128/aac.02139-15.

Full text
Abstract:
ABSTRACTThe urgent need of effective therapies for methicillin-resistantStaphylococcus aureus(MRSA) infective endocarditis (IE) is a cause of concern. We aimed to ascertain thein vitroandin vivoactivity of the older antibiotic fosfomycin combined with different beta-lactams against MRSA and glycopeptide-intermediate-resistantS. aureus(GISA) strains. Time-kill tests with 10 isolates showed that fosfomycin plus imipenem (FOF+IPM) was the most active evaluated combination. In an aortic valve IE model with two strains (MRSA-277H and GISA-ATCC 700788), the following intravenous regimens were compar
APA, Harvard, Vancouver, ISO, and other styles
39

Dennison, James E., Philip L. Bigelow, and Melvin E. Andersen. "Occupational exposure limits in the context of solvent mixtures, consumption of ethanol, and target tissue dose." Toxicology and Industrial Health 20, no. 6-10 (2004): 165–75. http://dx.doi.org/10.1191/0748233704th203oa.

Full text
Abstract:
Individuals are exposed to mixtures, and never to single chemicals. Depending on the composition of the elements of mixtures, significant toxicological interactions between the components may occur. These interactions are complex and often difficult to predict, ranging from synergistic to additive and subadditive interactions. The nature of the interactions needs to be evaluated as the target tissue dose of the active form of each chemical. PBPK modeling is an effective tool for determining the target tissue dose and evaluating these interactions when data are available for model development.
APA, Harvard, Vancouver, ISO, and other styles
40

Hu, Jing, Zhengbao Zhang, Senwei Lin, et al. "Application of All-Ages Lead Model Based on Monte Carlo Simulation of Preschool Children’s Exposure to Lead in Guangdong Province, China." Sustainability 15, no. 2 (2023): 1068. http://dx.doi.org/10.3390/su15021068.

Full text
Abstract:
Introduction: Lead (Pb) poisoning in children is a major public health issue worldwide. The physiologically based pharmacokinetic model (PBPK model) has been extensively utilized in Pb exposure risk assessment and can connect external exposure with biological monitoring data. This study aimed to combine a Monte Carlo simulation with the all-ages lead model (ALLM) to quantify the heterogeneity and uncertainty of certain parameters in the population. The parameters of the all-ages lead model based on Monte Carlo simulation (ALLM + MC) were localized in Guangdong Province. Our study discusses the
APA, Harvard, Vancouver, ISO, and other styles
41

Ibrahim, A. H., H. Barry, and C. M. Hughes. "A cross-sectional survey of general practitioners’ experiences with, views of, and attitudes towards, practice-based pharmacists." International Journal of Pharmacy Practice 29, Supplement_1 (2021): i24—i25. http://dx.doi.org/10.1093/ijpp/riab015.029.

Full text
Abstract:
Abstract Introduction Five-year pilot schemes were announced in both England and Northern Ireland (NI) to integrate practice-based pharmacists (PBPs) into general practices. The NI scheme anticipates that there will be 300 whole time equivalent PBPs in post by the end of the pilot (2020/2021).[1] There is little existing UK literature on PBPs’ role evolution and few studies have explored general practitioners’ (GPs) experiences of pharmacist integration into primary care practice. Aim To investigate GPs’ experiences with PBPs, their views about the PBP role and its impact upon patients and GPs
APA, Harvard, Vancouver, ISO, and other styles
42

Jayawardena, Thilina U., Lei Wang, K. K. Asanka Sanjeewa, Sang In Kang, Jung-Suck Lee, and You-Jin Jeon. "Antioxidant Potential of Sulfated Polysaccharides from Padina boryana; Protective Effect against Oxidative Stress in In Vitro and In Vivo Zebrafish Model." Marine Drugs 18, no. 4 (2020): 212. http://dx.doi.org/10.3390/md18040212.

Full text
Abstract:
Elevated levels of reactive oxygen species (ROS) damage the internal cell components. Padina boryana, a brown alga from the Maldives, was subjected to polysaccharide extraction. The Celluclast enzyme assisted extract (PBE) and ethanol precipitation (PBP) of P. boryana were assessed against hydrogen peroxide (H2O2) induced cell damage and zebra fish models. PBP which contains the majority of sulfated polysaccharides based on fucoidan, showed outstanding extracellular ROS scavenging potential against H2O2. PBP significantly declined the intracellular ROS levels, and exhibited protection against
APA, Harvard, Vancouver, ISO, and other styles
43

Audi, Said H., Anthony Cammarata, Anne V. Clough, Ranjan K. Dash, and Elizabeth R. Jacobs. "Quantification of mitochondrial membrane potential in the isolated rat lung using rhodamine 6G." Journal of Applied Physiology 128, no. 4 (2020): 892–906. http://dx.doi.org/10.1152/japplphysiol.00789.2019.

Full text
Abstract:
Mitochondrial membrane potential (Δψm) plays a key role in vital mitochondrial functions, and its dissipation is a hallmark of mitochondrial dysfunction. The objective of this study was to develop an experimental and computational approach for estimating Δψm in intact rat lungs using the lipophilic fluorescent cationic dye rhodamine 6G (R6G). Rat lungs were excised and connected to a ventilation-perfusion system. The experimental protocol consisted of three single-pass phases, loading, washing, and uncoupling, in which the lungs were perfused with R6G-containing perfusate, fresh R6G-free perfu
APA, Harvard, Vancouver, ISO, and other styles
44

Tudora, Anabella, and Franz-Josef Hambsch. "Parameterisation of the residual temperature distribution based on the modelling of successive emission of prompt neutrons." EPJ Web of Conferences 169 (2018): 00025. http://dx.doi.org/10.1051/epjconf/201816900025.

Full text
Abstract:
A new deterministic modelling taking into account the successive emission of prompt neutrons from initial fragments of a fragmentation range {A, Z, TKE} constructed as in the Point-by-Point (PbP) treatment is described. The good agreement of different prompt emission quantities obtained from this modelling (e.g. v(A), v(TKE), E-γ(A), E-γ(TKE), etc.) with the experimental data and the results of the PbP model and other Monte-Carlo models validates the present modelling of sequential emission. The distributions of different residual quantities, including the residual temperature distributions P(
APA, Harvard, Vancouver, ISO, and other styles
45

Shea, T. C., J. R. Mason, A. M. Storniolo, et al. "Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy." Journal of Clinical Oncology 10, no. 3 (1992): 464–73. http://dx.doi.org/10.1200/jco.1992.10.3.464.

Full text
Abstract:
PURPOSE The trial was undertaken to study the effect of administering granulocyte-macrophage colony-stimulating factor (GM-CSF) with and without peripheral-blood progenitor cells (PBPC) on the hematologic and nonhematologic toxicity observed with multiple cycles of high-dose carboplatin chemotherapy. PATIENTS AND METHODS Eighteen patients with a variety of solid tumors received a total of 40 cycles of carboplatin, 1,200 mg/m2 per cycle, administered by continuous infusion over 96 hours. All 40 courses were administered with a daily 4-hour intravenous (IV) infusion of either 5 or 10 micrograms/
APA, Harvard, Vancouver, ISO, and other styles
46

Kallidaikurichi Srinivasan, Karthikeyan, Anthony Gallagher, Niall O’Brien, et al. "Proficiency-based progression training: an ‘end to end’ model for decreasing error applied to achievement of effective epidural analgesia during labour: a randomised control study." BMJ Open 8, no. 10 (2018): e020099. http://dx.doi.org/10.1136/bmjopen-2017-020099.

Full text
Abstract:
BackgroundTraining procedural skills using proficiency-based progression (PBP) methodology has consistently resulted in error reduction. We hypothesised that implementation of metric-based PBP training and a valid assessment tool would decrease the failure rate of epidural analgesia during labour when compared to standard simulation-based training.MethodsDetailed, procedure-specific metrics for labour epidural catheter placement were developed based on carefully elicited expert input. Proficiency was defined using criteria derived from clinical performance of experienced practitioners. A PBP c
APA, Harvard, Vancouver, ISO, and other styles
47

Hanke, Nina, Sebastian Frechen, Daniel Moj, et al. "PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin." CPT: Pharmacometrics & Systems Pharmacology 7, no. 10 (2018): 647–59. http://dx.doi.org/10.1002/psp4.12343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Zubair, Abba, Rhonda Grant, Han Tun, et al. "Platelet Count Is a Sensitive Predictor of Bone Marrow Reserve and Autologous Peripheral Blood Progenitor Cell Mobilization." Blood 106, no. 11 (2005): 5280. http://dx.doi.org/10.1182/blood.v106.11.5280.5280.

Full text
Abstract:
Abstract Background: Previous studies have proposed combination of various factors that predict poor mobilization after GCSF stimulation. However, there is no single clinical or laboratory test that reliably correlates with bone marrow reserve and PBPC mobilization. Peripheral blood CD34+ cell count (pCD34) reliably correlates with PBPC mobilization and yield but only after GCSF administration. Methods: We have prospectively followed 36 autologous PBPC transplant candidates, from the time of initial evaluation to transplant, to evaluate factors the correlate with bone marrow reserve and autolo
APA, Harvard, Vancouver, ISO, and other styles
49

Liu, Xingbang, and Yong He. "Effect and Clinical Value of Protective Motivation Intervention Rehabilitation Model on Pain Perception and Dysfunction in Patients with Lumbar Disc Herniation: Based on a Retrospective Cohort Study." Computational and Mathematical Methods in Medicine 2022 (August 30, 2022): 1–8. http://dx.doi.org/10.1155/2022/5911889.

Full text
Abstract:
Objective. To examine the potential medical benefits of protective motivation intervention rehabilitation mode on pain perception and dysfunction in patients with lumbar disc herniation (LDH). Methods. 140 LDH patients hospitalized from January 2021 to September 2021 were totally selected. The control group received regular rehabilitation, and the research group received protective motivation intervention rehabilitation. The comparisons of scores of disease knowledge, visual analogue scale (VAS), pain belief and perception scale (PBPI), Japanese Orthopedic Association Score (JOA), Roland-Morri
APA, Harvard, Vancouver, ISO, and other styles
50

Amice, Basile, Harvey Ho, En Zhang, and Chris Bullen. "Physiologically Based Pharmacokinetic Modelling for Nicotine and Cotinine Clearance in Pregnant Women." Frontiers in Pharmacology 12 (July 20, 2021). http://dx.doi.org/10.3389/fphar.2021.688597.

Full text
Abstract:
Introduction: Physiologically based pharmacokinetic (PBPK) models for the absorption, disposition, metabolism and excretion (ADME) of nicotine and its major metabolite cotinine in pregnant women (p-PBPK) are rare. The aim of this short research report is to present a p-PBPK model and its simulations for nicotine and cotinine clearance.Methods: The maternal-placental-fetal compartments of the p-PBPK model contain a total of 16 compartments representing major maternal and fetal organs and tissue groups. Qualitative and quantitative data of nicotine and cotinine disposition and clearance have bee
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!